Quad beats two standard AIDS drugs; Johnson replaces Gold as Dendreon chairman;

 @FierceBiotech: Researchers shatter record with U.S.-China genomic data transfer. News | Follow @FierceBiotech

@JohnCFierce: Rodman's Michael King says 'whoops' on Amylin, believes Vivus and MannKind (huh?) next likely diabetes targets. Item | Follow @JohnCFierce

 @RyanMFierce: A good job rounding up the early-stage biotech VC usual suspects. More | Follow @RyanMFierce

> Gilead's ($GILD) new AIDS drug Quad slightly outperformed two standard once-a-day treatments in a head-to-head study. Report

> John Johnson has replaced Mitch Gold as chairman of Dendreon ($DNDN). Story

> The EMA has approved Eisai's application to extend the use of once-daily Zonegran (zonisamide) from adjunctive therapy to also include monotherapy for the treatment of partial seizures (with or without secondary generalisation) in adults with newly diagnosed epilepsy. Release

> Palatin Technologies has priced $35 million in stock. Release

Pharma News

@FiercePharma: Jefferies analysts like India's Cipla, Ranbaxy, Sun Pharma, because of emerging markets sales. Item | Follow @FiercePharma

> Will Amylin buy favor AZ's Simon Lowth in CEO contest? More

> Purdue aims to extend OxyContin monopoly with test in kids. Article

> Icahn looks askance at Forest CEO's stock trading. Story

Medical Device News

@FierceMedDev: CareFusion has staged a Class I recall of some of its infant breathing devices. Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: Roche continues to expand its diagnostics business with an FDA nod for a new HIV test. Story | Follow @DamianFierce

> SEC suspends China Medical trading amid accuracy concerns. More

> CareFusion stages Class I recall of infant breathing device. News

> CVRx launches registry to track hypertension-device patients. Item

> Wright looking to recapture profits with foot-reconstruction tech. Article

Biotech Research News

> Promising mouse study lays foundation for startup's autism drug program. Article

> In breakthrough, stem cell transplants reverse diabetes in mice. Story

> Texas cancer research funding effort may shift to startups. Item

> Mayo Clinic researchers find novel way to repair MS damage. News

Pharma Manufacturing News

> GlaxoSmithKline's Witty says manufacturing must become more efficient. More

> J&J recalls 69,000 units of K-Y vaginal lubricant. News

> United snags Glaxo buildings as it completes expansion. Story

> ScinoPharm building new cancer injectables plant in China. Article

Biomarkers News

> Marker helps docs pick kids' bone cancer treatment. Story

> Developing proteomic signatures focus pancreatic cancer therapy. Article

> Heart size distorts biomarker levels. More

> Apolipoproteins mark diabetic visual loss. Item

> Biomarkers spot hep C liver disease. Story

And Finally… Creatine transporter deficiency--an absence of creatine in the brain--causes an energy metabolism deficit that causes severe speech problems, developmental delay, seizures and profound mental retardation in boys who suffer from autism. Now investigators at the University of Cincinnati and the Cincinnati Children's Hospital Medical Center have found an old drug that promises a new way to treat the disease in rodents. And they are handing it over to a startup that is laying plans to test it in humans. Story

 

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.